These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21269530)

  • 41. Northern California. Charting the future of reform.
    Schneider P
    Healthc Inform; 1998 Apr; 15(4):60-1. PubMed ID: 10180062
    [No Abstract]   [Full Text] [Related]  

  • 42. Suspend NHS competition rules in London to allow for urgent remodelling of healthcare, says think tank.
    Limb M
    BMJ; 2013 Jun; 346():f4120. PubMed ID: 23804185
    [No Abstract]   [Full Text] [Related]  

  • 43. Making a commitment to quality: development of the quality assurance programme in Chile, 1991-1999.
    Tassara GG
    Int J Qual Health Care; 1999 Oct; 11(5):443-5. PubMed ID: 10561039
    [No Abstract]   [Full Text] [Related]  

  • 44. Health sector liability under the Trade Practices Act.
    Kamvounias P
    Aust Health Rev; 1999; 22(1):81-96. PubMed ID: 10387908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Entry and regulation: evidence from health care professions.
    Schaumans C; Verboven F
    Rand J Econ; 2008; 39(4):949-72. PubMed ID: 19585707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new policy framework for health care markets.
    Butler SM
    Health Aff (Millwood); 2004; 23(2):22-4. PubMed ID: 15046127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [From idea to standard care-a field report].
    Herberz C; Steidl R; Werner P; Hagen J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Mar; 61(3):298-303. PubMed ID: 29383393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Markets, Prices, And Incentives.
    Weil AR
    Health Aff (Millwood); 2015 Jun; 34(6):902. PubMed ID: 26056192
    [No Abstract]   [Full Text] [Related]  

  • 49. [Can we learn from the Dutch health reform?].
    Bergman SE
    Lakartidningen; 2011 Oct 19-25; 108(42):2103-4. PubMed ID: 22165538
    [No Abstract]   [Full Text] [Related]  

  • 50. Backstop Price Caps in Commercial Health Care Markets.
    Lusk JB; McDevitt RC
    JAMA; 2021 Jul; 326(3):276-277. PubMed ID: 34283189
    [No Abstract]   [Full Text] [Related]  

  • 51. Backstop Price Caps in Commercial Health Care Markets-Reply.
    Chernew ME; Pany MJ
    JAMA; 2021 Jul; 326(3):277. PubMed ID: 34283187
    [No Abstract]   [Full Text] [Related]  

  • 52. Power and Purchasing: Why Strategic Purchasing Fails.
    Greer SL; Klasa K; VAN Ginneken E
    Milbank Q; 2020 Sep; 98(3):975-1020. PubMed ID: 32749005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Working with layers: The governance and regulation of healthcare quality in an institutionally layered system.
    van de Bovenkamp HM; Stoopendaal A; Bal R
    Public Policy Adm; 2017 Jan; 32(1):45-65. PubMed ID: 28596640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Managed competition" for Ireland? The single versus multiple payer debate.
    Mikkers M; Ryan P
    BMC Health Serv Res; 2014 Sep; 14():442. PubMed ID: 25261074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is the quality of data in an electronic medical record sufficient for assessing the quality of primary care?
    Barkhuysen P; de Grauw W; Akkermans R; Donkers J; Schers H; Biermans M
    J Am Med Inform Assoc; 2014; 21(4):692-8. PubMed ID: 24145818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the impact of cancer among Dutch non-Hodgkin lymphoma survivors compared with their American counterparts: a cross-national study.
    Oerlemans S; Smith SK; Crespi CM; Zimmerman S; van de Poll-Franse LV; Ganz PA
    Psychooncology; 2013 Jun; 22(6):1258-65. PubMed ID: 22833503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The practice of markets in Dutch health care: are we drinking from the same glass?
    Bal R; Zuiderent-Jerak T
    Health Econ Policy Law; 2011 Jan; 6(1):139-45. PubMed ID: 21269530
    [No Abstract]   [Full Text] [Related]  

  • 58. Managed competition in The Netherlands: lessons from five years of health care reform.
    van de Ven W; Rutten F
    Aust Health Rev; 1995; 18(1):9-27. PubMed ID: 10141966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of purchaser competition in the Dutch health system: is the glass half full or half empty?
    Schut FT; van de Ven WP
    Health Econ Policy Law; 2011 Jan; 6(1):109-23. PubMed ID: 21269527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Netherlands: health system review.
    Schäfer W; Kroneman M; Boerma W; van den Berg M; Westert G; Devillé W; van Ginneken E
    Health Syst Transit; 2010; 12(1):v-xxvii, 1-228. PubMed ID: 21132996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.